The prognosis of many patients with chemotherapy-refractory or multiply relapsed CD30+ non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) still remains poor, and novel therapeutic approaches are warranted to address this unmet clinical need. In light of this consideration, we designed and pre-clinically validated a chimeric antigen receptor (CAR) construct characterized by a novel anti-CD30 single-chain variable-fragment cassette, linked to CD3ζ by the signaling domains of two co-stimulatory molecules, namely CD28.4-1BB or CD28.OX40. We found that CAR.CD30 T cells exhibit remarkable cytolytic activity in vitro against both HL and NHL cell lines, with sustained proliferation and pro-inflammatory cytokine production, even after multiple and sequential lymphoma-cell challenges. CAR.CD30 T cells also demonstrated anti-lymphoma activity in two in vivo xenograft immune-deficient mouse models of metastatic HL and NHL. We observed that administration of CAR.CD30 T cells, incorporating the CD28.OX40 co-stimulatory domains and manufactured in the presence of interleukin 7 and interleukin 15, were associated with the best overall survival in the treated mice, along with establishment of a long-term immunological memory able to protect mice from further tumor re-challenge. Our data indicate that, in the context of in vivo systemic metastatic xenograft mouse models, the co-stimulatory machinery of CD28.OX40 is crucial for improving persistence, in vivo expansion and proliferation of CAR.CD30 T cells upon tumor encounter. The CD28.OX40 co-stimulatory combination is ultimately responsible for the anti-tumor efficacy of the approach, paving the way to translate this therapeutic strategy into clinical use for patients with CD30+ HL and NHL.

Guercio, M., Orlando, D., Cecca, S. D., Sinibaldi, M., Boffa, I., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., Bovetti, K., Manni, S., Caruana, I., Ciccone, R., Bufalo, F. D., Merli, P., Vinti, L., Girardi, K., Ruggeri, A., De Stefanis, C., Pezzullo, M., Giorda, E., Scarsella, M., De Vito, R., Barresi, S., Ciolfi, A., Tartaglia, M., Moretta, L., Locatelli, F., Quintarelli, C., De Angelis, B., CD28.OX40 co-stimulatory combination is high associated activity with of CAR.CD30 long in vivoT persistence cells and, <<HAEMATOLOGICA>>, 2021; 106 (4): 987-999. [doi:10.3324/haematol.2019.231183] [https://hdl.handle.net/10807/229218]

CD28.OX40 co-stimulatory combination is high associated activity with of CAR.CD30 long in vivoT persistence cells and

Locatelli, Franco
Writing – Review & Editing
;
2021

Abstract

The prognosis of many patients with chemotherapy-refractory or multiply relapsed CD30+ non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) still remains poor, and novel therapeutic approaches are warranted to address this unmet clinical need. In light of this consideration, we designed and pre-clinically validated a chimeric antigen receptor (CAR) construct characterized by a novel anti-CD30 single-chain variable-fragment cassette, linked to CD3ζ by the signaling domains of two co-stimulatory molecules, namely CD28.4-1BB or CD28.OX40. We found that CAR.CD30 T cells exhibit remarkable cytolytic activity in vitro against both HL and NHL cell lines, with sustained proliferation and pro-inflammatory cytokine production, even after multiple and sequential lymphoma-cell challenges. CAR.CD30 T cells also demonstrated anti-lymphoma activity in two in vivo xenograft immune-deficient mouse models of metastatic HL and NHL. We observed that administration of CAR.CD30 T cells, incorporating the CD28.OX40 co-stimulatory domains and manufactured in the presence of interleukin 7 and interleukin 15, were associated with the best overall survival in the treated mice, along with establishment of a long-term immunological memory able to protect mice from further tumor re-challenge. Our data indicate that, in the context of in vivo systemic metastatic xenograft mouse models, the co-stimulatory machinery of CD28.OX40 is crucial for improving persistence, in vivo expansion and proliferation of CAR.CD30 T cells upon tumor encounter. The CD28.OX40 co-stimulatory combination is ultimately responsible for the anti-tumor efficacy of the approach, paving the way to translate this therapeutic strategy into clinical use for patients with CD30+ HL and NHL.
2021
Inglese
Guercio, M., Orlando, D., Cecca, S. D., Sinibaldi, M., Boffa, I., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., Bovetti, K., Manni, S., Caruana, I., Ciccone, R., Bufalo, F. D., Merli, P., Vinti, L., Girardi, K., Ruggeri, A., De Stefanis, C., Pezzullo, M., Giorda, E., Scarsella, M., De Vito, R., Barresi, S., Ciolfi, A., Tartaglia, M., Moretta, L., Locatelli, F., Quintarelli, C., De Angelis, B., CD28.OX40 co-stimulatory combination is high associated activity with of CAR.CD30 long in vivoT persistence cells and, <<HAEMATOLOGICA>>, 2021; 106 (4): 987-999. [doi:10.3324/haematol.2019.231183] [https://hdl.handle.net/10807/229218]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/229218
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 38
social impact